Smarter Cancer Care
Genomic Health delivers the promise and value of precision medicine
with the Oncotype IQ portfolio of genomic tests.

Landmark TAILORx Results

The long-awaited results of the Trial Assigning IndividuaLized Options for Treatment (TAILORx) definitively identified the vast majority of women with early stage breast cancer who will receive no benefit from chemotherapy, and the minority for whom chemotherapy can be life-saving.

What Is the Test
The Oncotype DX test reveals the underlying tumour biology to help guide treatment decisions.
Getting Tested
The Oncotype DX test should be used when the benefit of chemotherapy for a patient is uncertain.
Latest TAILORx Data
After 5 years, 99% of women with a low Oncotype DX Breast Recurrence Score (<11) were recurrence-free with hormone therapy alone.
Resources

Visit these pages for further information on the Oncotype DX test and FAQs.

Contact Us

Get in Touch
Making cancer care smarter.™
X

This site uses cookies. These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is used only to improve the website. By visiting this website, you agree that we can place these types of cookies on your device.